Spica Healthcare β€” Unit of Grover Hospital, Bathinda
HomeHealth Guides & BlogsMedical Oncology & ChemotherapyGastric Adenocarcinoma: HER2, Claudin 18.2, and MSI-H Biomarker-Directed Frontline Systemic Regimens
Medical Oncology & Chemotherapy

Gastric Adenocarcinoma: HER2, Claudin 18.2, and MSI-H Biomarker-Directed Frontline Systemic Regimens

11 min read
Sep 8, 2026
Spica Healthcare Clinical & Surgical Protocol Illustration #134

Clinical Summary & Key Takeaways

A clinical medical oncology guide on precision Biomarker-Driven Stomach Cancer Therapy, analyzing HER2 testing (ToGA / KEYNOTE-811), Claudin 18.2 monoclonal antibodies (Zolbetuximab - SPOTLIGHT trial), Nivolumab in PD-L1 CPS >=5 (CheckMate 649), and perioperative FLOT chemotherapy.

CRITICAL CLINICAL RED FLAG: Unexplained persistent dyspepsia, early satiety, progressive difficulty swallowing (dysphagia), iron deficiency anemia, or unintentional weight loss in an adult demands prompt upper gastrointestinal endoscopy and biopsy.

1. The Modern Biomarker Landscape in Gastric & GEJ Cancer

Advanced gastric adenocarcinoma requires upfront molecular testing on diagnostic endoscopic biopsy specimens to guide tailored systemic regimens:

  • HER2/neu Overexpression: Present in 15–20% of gastric adenocarcinomas (predominantly intestinal subtype and gastroesophageal junction tumors).

  • Claudin 18.2 Positivity: Expressed in up to 35–40% of gastric cancers (defined as >=75% of tumor cells showing moderate-to-strong membranous staining).

  • PD-L1 Combined Positive Score (CPS): Quantified via 28-8 or 22C3 IHC assays (CPS >=5 identifies major immunotherapy responders).

  • Microsatellite Instability-High (MSI-H / dMMR): Present in 5–8% of gastric tumors, exhibiting exceptional sensitivity to checkpoint inhibitors.

2. Frontline Targeted Combinations: The Trial Evidence

Biomarker-directed therapeutic algorithms:

  1. HER2-Positive (KEYNOTE-811 Trial): Trastuzumab + Pembrolizumab + Fluoropyrimidine/Platinum doublet yields objective response rates exceeding 74%.

  2. Claudin 18.2-Positive / HER2-Negative (SPOTLIGHT & GLOW Trials): Zolbetuximab (anti-Claudin 18.2 chimeric IgG1 antibody) + mFOLFOX6 or CAPOX significantly prolongs progression-free and overall survival.

  3. PD-L1 CPS >=5 / HER2-Negative (CheckMate 649 Trial): Nivolumab + FOLFOX/CAPOX establishes standard frontline therapy, reducing mortality risk by 29%.

"Stomach cancer is no longer treated with one-size-fits-all chemotherapy. Comprehensive biomarker profiling for HER2, Claudin 18.2, and PD-L1 unlocks targeted therapies that dramatically improve survival." β€” Dr. Neha Gupta
Spica Healthcare Clinical & Surgical Protocol Illustration #134
Spica Healthcare Clinical & Surgical Protocol Illustration #134

3. Perioperative FLOT Regimen for Resectable Gastric Cancer

For resectable cT2 or node-positive gastric cancer, 4 pre-operative and 4 post-operative cycles of FLOT (5-FU, Leucovorin, Oxaliplatin, Docetaxel) significantly improves complete R0 resection rates and 5-year survival compared to older ECF regimens.

CLINICAL CAUTION: HER2 testing in gastric cancer must follow gastric-specific scoring criteria (basolateral membrane staining and tumor heterogeneity); applying breast cancer HER2 criteria leads to false-negative under-treatment.

4. Post-Gastrectomy Nutritional Management & Vitamin B12

Following radical total or subtotal gastrectomy, routine lifelong intramuscular Vitamin B12 supplementation, oral iron, and small frequent high-protein meals prevent dumping syndrome and megaloblastic anemia.

5. Peer-Reviewed References & Clinical Guidelines

1. Zolbetuximab plus mFOLFOX6 in Claudin 18.2-Positive Gastric Cancer (SPOTLIGHT Trial) β€” Lancet, 2023; 401(10389): 1655-1668.

2. First-line Nivolumab plus Chemotherapy for Advanced Gastric Cancer (CheckMate 649) β€” Lancet, 2021; 398(10294): 27-40.

Frequently Asked Patient Questions

Limb Salvage with modular titanium megaprosthesis removes the tumor completely while preserving the limb, allowing patients to walk, work, and maintain full social independence without the physical disability of an artificial limb.

Dr. Neha Gupta - Clinical Director & Senior Medical Oncologist

Senior Consultant & Clinical Director β€” Medical Oncology

MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

Share this medical guide:
WhatsApp
Director-Led Clinical Breakthroughs

Signature Surgical Innovations & Techniques

Proprietary surgical methodologies and precision protocols pioneered by our senior directors to minimize trauma, protect natural anatomy, and accelerate recovery.

1 of 13
Comprehensive Bone Cancer Oncology & Limb Preservation
Click to Watch Video Demonstration
95%+ Limb Salvage & MAP Chemotherapy
Multidisciplinary Limb Salvage, MAP Chemotherapy & Modular Megaprosthetics

Comprehensive Bone Cancer Oncology & Limb Preservation

Dr. Deepak Garg (Orthopaedic Surgical Oncology - RGCI Delhi Trained) and Dr. Neha Gupta (Medical Oncology) co-lead the Bone Cancer & Sarcoma Center at Spica Healthcare. Integrating intensive multi-agent neoadjuvant chemotherapy protocols (MAP: High-Dose Methotrexate, Doxorubicin, Cisplatin for Osteosarcoma; VIDE: Vincristine, Ifosfamide, Doxorubicin, Etoposide for Ewing Sarcoma) with 3D computer-navigated limb salvage surgery and modular titanium megaprosthetic joint reconstruction, 5-year survival rates exceed 75% to 80% while saving over 95% of patients from limb amputation.

Key Advantages Over Conventional Surgery:
Coordinated Surgical & Medical Oncology: Seamless dual leadership under Dr. Deepak Garg & Dr. Neha Gupta
95%+ Limb Preservation Rate: Wide oncological bone resection avoiding traumatic limb amputations
High-Grade Sarcoma Chemotherapy: Standardized MAP and VIDE protocols delivering high tumor necrosis rates (>90%)
Custom Modular Megaprostheses: Immediate joint restoration with biological tendon ingrowth collars
Why Families & Physicians Trust Spica

World-Class Clinical Precision, Built on Compassion

Spica Healthcare β€” Bone and Cancer Institute, Bathinda β€” is South-Western Punjab's premier super-speciality centre led by AIIMS and Tata Memorial fellowship-trained directors.

AIIMS & Tata Memorial Alumni25+ Yrs Combined Senior Leadership

15,000+ Complex Surgeries & 100% Director-Led Evaluations

Every diagnostic MRI review, surgical staging, and operation is personally directed by chief clinical specialists β€” Dr. Deepak Garg (Orthopaedic Oncology & Robotics) and Dr. Neha Gupta (Medical Oncology) β€” guaranteeing zero junior proxies.

15,000+Surgeries Completed
95%+Limb Salvage Rate
<0.3%Infection Benchmark
Pre-Op 3D Virtual Planning 100% Direct Director OPD Day-1 Walking Protocol
Sub-Millimeter Accuracy

3D Navigated Robotics & Day-1 Walking

Sub-millimeter implant positioning and soft-tissue ligament balancing ensuring patients walk comfortably within 24 hours of total knee replacement.

ROSA Robotics & Stryker Nav
Malwa Punjab Exclusive

Limb-Salvage Over Amputation

South-West Punjab's only dedicated centre for modular titanium megaprosthesis, saving natural limbs and functions in 95%+ of bone cancer patients.

Modular Megaprosthesis
0-Out-Of-Pocket Options

100% Cashless PM-JAY & TPAs

Full cashless coverage for Ayushman Bharat (PM-JAY), Punjab Govt Health Schemes, ECHS, and 30+ private insurance networks with on-desk approvals.

Ayushman + 30+ TPAs Empanelled
24/7 Tertiary Ready

Class-100 Laminar Flow OTs & ICU

Positive-pressure HEPA filtered theatres minimizing infection rates below international benchmarks with 24/7 dedicated critical care backup.

Spica Healthcare Bathinda
Expert Surgical Directors

Meet the Doctors at Spica Healthcare

Fellowship-trained surgical directors from AIIMS & Tata Memorial providing compassionate, world-class tertiary care in super-speciality orthopaedics and medical oncology.

Dr. Neha Gupta - Clinical Director & Senior Medical Oncologist

Dr. Neha Gupta

Senior Consultant & Clinical Director β€” Medical Oncology

13+ Yrs Exp

MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

Medical Oncology & ChemotherapyImmunotherapy & Targeted OncologyPrecision Oncology & Cancer GenomicsPreventive Cancer ScreeningPalliative & Supportive OncologyHormonal TherapyComprehensive Cancer Treatments
Dr. Deepak Garg - Director & Senior Joint Replacement, Spine and Orthopaedic Oncologist

Dr. Deepak Garg

Senior Consultant & Clinical Director β€” Orthopaedic Oncology & Robotic Joint Surgery

16+ Yrs Exp

MBBS (TNMC Mumbai), DNB Orthopaedics (PGI & SP Miraj), Fellowship Arthroplasty and Arthroscopy (Fortis Hospital, New Delhi), Fellowship Orthopaedic Oncology (Rajiv Gandhi Cancer Institute, New Delhi)

Orthopaedic Oncology & Bone Tumors3D Robotic Joint ReplacementSports Injuries & ArthroscopyTrauma & Fracture ReconstructionGeneral Orthopaedics & Spine CareComprehensive Cancer Treatments
Community Health & Academic Outreach

Upcoming Health Camps & Academic Events

Free OPD screening camps, director-led masterclasses, and national oncology representations by Spica Healthcare.

Curious what families & patients experience

Hear what our patients are saying

Real stories from patients who recovered through limb preservation surgery, 3D robotic joint replacements, and precision cancer care at Spica Healthcare β€” Grover Hospital, Bathinda.

Health Knowledge & Clinical Guides

Doctor-Authored Health Guides

Evidence-based surgical recovery roadmaps, robotic joint protocols, and precision oncology insights written by our clinical directors.